

Peter C Albertsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3155923/publications.pdf>

Version: 2024-02-01

93
papers

5,251
citations

249298

26
h-index

93651

72
g-index

109
all docs

109
docs citations

109
times ranked

5427
citing authors

#	ARTICLE	IF	CITATIONS
1	PSA testing, cancer treatment, and prostate cancer mortality reduction: What is the mechanism?. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 78-81.	0.8	8
2	So why do surgeons continue to place drains?. BJU International, 2022, 129, 131-131.	1.3	0
3	How many cores are enough? Optimizing the transperineal prostate biopsy template. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 191.e1-191.e7.	0.8	5
4	Prostate-specific Antigen Screening Using the Traditional Cut Point of 3 ng/ml: Con. European Urology Focus, 2021, 7, 501-502.	1.6	2
5	Prostate cancer: the interplay between genetics and the environment. BJU International, 2021, 127, 615-616.	1.3	0
6	Re: Trends and practices for managing low-risk prostate cancer: A SEER-Medicare study. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	0
7	Prostate cancer screening: a new way forward or another false start?. Nature Reviews Urology, 2021, 18, 579-580.	1.9	2
8	Prostate cancer screening and treatment: where have we come from and where are we going?. BJU International, 2020, 126, 218-224.	1.3	39
9	â€œCase of the monthâ€™ from UConn Health, Farmington, CT, USA: management of a giant paraganglioma. BJU International, 2020, 126, 551-553.	1.3	1
10	EDITORIAL COMMENT. Urology, 2020, 145, 195-196.	0.5	0
11	Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancerâ€™29-Year Follow-up. European Urology, 2020, 78, 471.	0.9	2
12	Estimating the threat posed by prostate cancer. BJU International, 2020, 125, 480-481.	1.3	1
13	William Halsted and Prostate Cancer Progression. European Urology, 2020, 77, 725-726.	0.9	0
14	Reconsidering Prostate Cancer Mortality â€™ The Future of PSA Screening. New England Journal of Medicine, 2020, 382, 1557-1563.	13.9	120
15	Patient Decision-making: Where Are We Going?. European Urology, 2019, 75, 908-909.	0.9	1
16	Centers of Excellence: What are Realistic Goals?. European Urology, 2019, 76, 187-188.	0.9	1
17	Editorial Comment. Journal of Urology, 2018, 199, 681-681.	0.2	0
18	Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiology and Drug Safety, 2018, 27, 340-348.	0.9	56

#	ARTICLE	IF	CITATIONS
19	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. <i>Urology Practice</i> , 2018, 5, 471-479.	0.2	1
20	Prostate cancer screening with prostate-specific antigen: Where are we going?. <i>Cancer</i> , 2018, 124, 453-455.	2.0	8
21	Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 528.e15-528.e20.	0.8	32
22	Is Tamsulosin Linked to Dementia in the Elderly?. <i>Current Urology Reports</i> , 2018, 19, 69.	1.0	7
23	Editorial Comment. <i>Urology</i> , 2018, 116, 142.	0.5	0
24	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	0.9	190
25	Insights from the PLCO trial about prostate cancer screening. <i>Cancer</i> , 2017, 123, 546-548.	2.0	2
26	Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer. <i>European Urology</i> , 2017, 72, 470.	0.9	1
27	Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data. <i>European Urology</i> , 2017, 71, 760-763.	0.9	45
28	Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. <i>European Journal of Cancer</i> , 2017, 87, 203.	1.3	3
29	Active Surveillance: A Ten-year Journey. <i>European Urology</i> , 2017, 72, 542-543.	0.9	3
30	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016, 118, 911-918.	1.3	5
31	Another Reason to Consider Active Surveillance. <i>European Urology</i> , 2016, 69, 582-583.	0.9	1
32	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. <i>Eur Urol</i> 2015;68:805-811. <i>European Urology</i> , 2016, 69, e131-e132.	0.9	1
33	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016, 115, 90-94.	2.9	38
34	Successful external validation of a model to predict other cause mortality in localized prostate cancer. <i>BMC Medicine</i> , 2016, 14, 25.	2.3	22
35	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 693-703.	0.9	207
36	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. <i>Journal of Urology</i> , 2016, 195, 321-329.	0.2	50

#	ARTICLE	IF	CITATIONS
37	Observational studies and the natural history of screen-detected prostate cancer. <i>Current Opinion in Urology</i> , 2015, 25, 232-237.	0.9	54
38	Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias?. <i>European Urology</i> , 2015, 68, 183-184.	0.9	9
39	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. <i>European Urology</i> , 2015, 67, 1019-1025.	0.9	15
40	Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. <i>European Urology</i> , 2015, 68, 805-811.	0.9	58
41	Prostate-specific Antigen Testing: Good or Bad?. <i>Oncologist</i> , 2015, 20, 233-235.	1.9	2
42	Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Urology</i> , 2015, 85, 92-100.	0.5	34
43	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015, 3, 1-138.	1.4	4
44	Radical prostatectomy reduces prostate cancer-specific mortality among men with intermediate-grade disease, but provides minimal benefit for men with low-grade and high-grade disease. <i>Evidence-Based Medicine</i> , 2014, 19, 176-176.	0.6	1
45	Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1460.	2.6	75
46	Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. <i>European Urology</i> , 2014, 65, 565-573.	0.9	276
47	Times, They Are a-Changing. <i>European Urology</i> , 2014, 66, 428-429.	0.9	0
48	MRI before Prostate Biopsy—Yes or No?. <i>Journal of Urology</i> , 2013, 190, 1978-1980.	0.2	1
49	Re: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. <i>European Urology</i> , 2013, 64, 512.	0.9	5
50	What Is the Risk Posed by Prostate Cancer?. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 169-174.	0.9	7
51	Robot-assisted Radical Prostatectomy — Fake Innovation or the Real Deal?. <i>European Urology</i> , 2012, 62, 365-367.	0.9	2
52	A tale of 2 perspectives. <i>Cancer</i> , 2012, 118, 3010-3011.	2.0	0
53	The prostate cancer conundrum revisited: Further insights. <i>Cancer</i> , 2012, 118, 5724-5727.	2.0	6
54	How Best To Use Our Tools?. <i>European Urology</i> , 2012, 62, 201-202.	0.9	2

#	ARTICLE	IF	CITATIONS
55	The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 615-623.	1.2	6
56	Measuring illness uncertainty in men undergoing active surveillance for prostate cancer. <i>Applied Nursing Research</i> , 2011, 24, 193-199.	1.0	31
57	Re: Active Surveillance Compared with Initial Treatment in Men with Low-Risk Prostate Cancer: A Decision Analysis. <i>European Urology</i> , 2011, 59, 882-883.	0.9	2
58	When is active surveillance the appropriate treatment for prostate cancer?. <i>Acta OncolÃ³gica</i> , 2011, 50, 120-126.	0.8	15
59	WHO International Consultation on Prostate Cancer: A summary. <i>Acta OncolÃ³gica</i> , 2011, 50, 155-160.	0.8	1
60	Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1335-1341.	0.8	266
61	Treatment of localized prostate cancer: when is active surveillance appropriate?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 394-400.	12.5	35
62	The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis. <i>Urology</i> , 2010, 75, 399-405.	0.5	25
63	A challenge to contemporary management of prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 12-13.	1.4	16
64	Androgen Deprivation in Prostate Cancer â€” Step by Step. <i>New England Journal of Medicine</i> , 2009, 360, 2572-2574.	13.9	17
65	The Treatment Paradigm Shifts Again on Prostate Cancer. <i>European Urology</i> , 2009, 55, 9-11.	0.9	4
66	Re: Radical Prostatectomy versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. <i>European Urology</i> , 2009, 55, 989-990.	0.9	3
67	The face of high risk prostate cancer. <i>World Journal of Urology</i> , 2008, 26, 205-210.	1.2	10
68	Should men with low-risk, localized prostate cancer choose active surveillance or undergo a robotic prostatectomy?. <i>Current Urology Reports</i> , 2008, 9, 1-2.	1.0	0
69	Should patients consider active surveillance?. <i>Cancer</i> , 2008, 112, 2631-2634.	2.0	3
70	Should men over the age of 65 years receive PSA screening? Argument against. <i>Nature Reviews Urology</i> , 2008, 5, 232-233.	1.4	2
71	Does radical prostatectomy provide a survival benefit as primary treatment for high-grade prostate cancer?. <i>Nature Reviews Urology</i> , 2007, 4, 68-69.	1.4	1
72	Commentary: Occult prostate cancer-imposter or the real deal?. <i>International Journal of Epidemiology</i> , 2007, 36, 281-282.	0.9	4

#	ARTICLE	IF	CITATIONS
73	13-Year Outcomes Following Treatment for Clinically Localized Prostate Cancer in a Population Based Cohort. <i>Journal of Urology</i> , 2007, 177, 932-936.	0.2	124
74	Against the motion. <i>European Urology</i> , 2006, 50, 379-380.	0.9	1
75	PSA and the conservative treatment of early prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 152-3.	0.4	4
76	Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?. <i>Acta Oncologica</i> , 2005, 44, 255-264.	0.8	23
77	What is the value of screening for prostate cancer in the US?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 536-537.	4.3	13
78	20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2095.	3.8	1,027
79	Prostate Cancer and the Will Rogers Phenomenon. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1248-1253.	3.0	369
80	Prostate-specific antigen: how to advise patients as the screening debate continues.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, 521-527.	0.6	5
81	VALIDATION OF INCREASING PROSTATE SPECIFIC ANTIGEN AS A PREDICTOR OF PROSTATE CANCER DEATH AFTER TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATION. <i>Journal of Urology</i> , 2004, 171, 2221-2225.	0.2	78
82	Lower urinary tract symptoms in the older male. <i>Connecticut Medicine</i> , 2003, 67, 487-90.	0.2	2
83	Which Results Justify the Means in Prostate Cancer Treatment?. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 30-32.	1.0	0
84	Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 3750-3757.	0.8	244
85	The Significance of Histology in Predicting the Natural History of Prostate Cancer. <i>Prostate Journal</i> , 2000, 2, 1-5.	0.2	0
86	Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer. <i>Annals of Internal Medicine</i> , 2000, 132, 566.	2.0	357
87	Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma. , 1998, 82, 1738-1748.		12
88	EDITORIAL: COMPUTER MODELING-WHAT SHOULD WE LOOK FOR?. <i>Journal of Urology</i> , 1998, 159, 934-934.	0.2	2
89	Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 975.	3.8	636
90	Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In Situ and in Vitro Expression of VEGF by Human Prostate Cancer Cells. <i>Journal of Urology</i> , 1997, 157, 2329-2333.	0.2	243

#	ARTICLE	IF	CITATIONS
91	The Impact of Co-morbidity on Life Expectancy Among Men with Localized Prostate Cancer. Journal of Urology, 1996, 156, 127-132.	0.2	227
92	Adenoid Cystic Carcinoma of Cowper's Gland. Journal of Urology, 1992, 147, 699-701.	0.2	16
93	Exercise interventions for men with prostate cancer. The Cochrane Library, 0, , .	1.5	2